Stock AMRX AMNEAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Real-time Estimate Cboe BZX
Other stock markets
 02:48:35 2024-04-25 pm EDT 		5-day change 1st Jan Change
5.695 USD -5.87% Intraday chart for Amneal Pharmaceuticals, Inc. +4.76% -7.50%
Apr. 24 Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise MT
Apr. 24 Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray DJ

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 121 and 67.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AMNEAL PHARMACEUTICALS, INC. Stock Amneal Pharmaceuticals, Inc.
-0.33% 1.87B
C-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 660B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.85% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.28% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.66% 219B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-9.98% 196B
A+
NOVARTIS AG Stock Novartis AG
+6.78% 199B
B-
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AMRX Stock
  4. Ratings Amneal Pharmaceuticals, Inc.